- Home
- LEGN vs CRSP Comparison
LEGN vs CRSP Comparison
Compare LEGN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- CRSP
- Stock Information
- Founded
- LEGN 2014
- CRSP 2013
- Country
- LEGN United States
- CRSP Switzerland
- Employees
- LEGN N/A
- CRSP N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGN Health Care
- CRSP Health Care
- Exchange
- LEGN Nasdaq
- CRSP Nasdaq
- Market Cap
- LEGN 6.3B
- CRSP 5.6B
- IPO Year
- LEGN 2020
- CRSP 2016
- Fundamental
- Price
- LEGN $31.46
- CRSP $70.29
- Analyst Decision
- LEGN Strong Buy
- CRSP Buy
- Analyst Count
- LEGN 12
- CRSP 18
- Target Price
- LEGN $73.36
- CRSP $72.59
- AVG Volume (30 Days)
- LEGN 1.2M
- CRSP 2.6M
- Earning Date
- LEGN 11-11-2025
- CRSP 11-04-2025
- Dividend Yield
- LEGN N/A
- CRSP N/A
- EPS Growth
- LEGN N/A
- CRSP N/A
- EPS
- LEGN N/A
- CRSP N/A
- Revenue
- LEGN $796,838,000.00
- CRSP $38,050,000.00
- Revenue This Year
- LEGN $69.31
- CRSP N/A
- Revenue Next Year
- LEGN $52.73
- CRSP $388.50
- P/E Ratio
- LEGN N/A
- CRSP N/A
- Revenue Growth
- LEGN 74.75
- CRSP N/A
- 52 Week Low
- LEGN $27.34
- CRSP $30.04
- 52 Week High
- LEGN $51.77
- CRSP $73.95
- Technical
- Relative Strength Index (RSI)
- LEGN 31.45
- CRSP 66.77
- Support Level
- LEGN $32.02
- CRSP $67.41
- Resistance Level
- LEGN $32.62
- CRSP $73.95
- Average True Range (ATR)
- LEGN 1.02
- CRSP 3.46
- MACD
- LEGN -0.09
- CRSP 0.88
- Stochastic Oscillator
- LEGN 6.87
- CRSP 77.22
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.